Acute Effect of Pamidronate on PTH Secretion in Postmenopausal Hemodialysis Patients with Secondary Hyperparathyroidism

American Journal of Kidney Diseases

Volumn 42, Issue 6, 2003, Pages 1221-1227

  Lu, Kuo Cheng ^b   Yeung, Lai King ^b   Lin, Shih Hua ^b   Lin, Yuh Feng ^b   Chu, Pauling ^a  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b NONE

Author keywords

Bisphosphonate; Calcium set point; Hemodialysis (HD); Pamidronate; Postmenopausal; Secondary hyperparathyroidism; Uremia

Indexed keywords

CALCIUM ION; PAMIDRONIC ACID; PARATHYROID HORMONE;

ADULT; AGED; ARTICLE; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG SCREENING; FEMALE; HEMODIALYSIS; HORMONE RELEASE; HUMAN; NEPHROTOXICITY; PARATHYROID HORMONE BLOOD LEVEL; POSTMENOPAUSE; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT;

EID: 0344826837     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2003.08.023     Document Type: Article

References (25)

1. Goodman WG: Recent developments in the management of secondary hyperparathyroidism. Kidney Int 59:1187-1201, 2001
2. McCarron DA, Muther RS, Lenfesty B, Bennett WM: Parathyroid function in persistent hyperparathyroidism: Relationship to gland size. Kidney Int 22:662-670, 1982
3. Mayer GP, Hurst JG: The sigmoidal relationship between parathyroid hormone secretion rate and plasma calcium concentrations in calves. Endocrinology 102:1036-1039, 1978
4. Brown EM: Four-parameter model of the sigmoidal relationship between parathyroid hormone release and extra-cellular calcium concentration in normal and abnormal parathyroid tissue. J Clin Endocrinol Metab 56:572-581, 1983
5. Felsenfeld AJ, Rodriguez M, Dunlay R, Llach F: A comparison of parathyroid-gland function in hemodialysis patients with different forms of renal osteodystrophy. Nephrol Dial Transplant 6:244-251, 1991
6. Lindberg JS, Moe SM: Osteoporosis in end stage renal disease. Semin Nephrol 19:115-122, 1999
7. Riggs BL, Khosla S, Melton LJ: An unitary model for involutional osteoporosis: Estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 13:763-773, 1998
8. Zaidi M, Blair HC, Moonga BS, Abe E, Huang CL-H: Osteoclastogenesis, bone resorption, and osteoclast-based therapeutics. J Bone Miner Res 18:599-609, 2003
9. Liberman UA, Weiss SR, Bröll J, et al: Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 333:1437-1443, 1995
10. Reid IR, Wattie DJ, Evans MC, Gamble GD, Stapleton JP, Cornish J: Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab 79:1595-1599, 1994
11. Malberti F, Farina M, Imbasciati E: The PTH-calcium curve and the set point of calcium in primary and secondary hyperparathyroidism. Nephrol Dial Transplant 14:2398-2406, 1999
12. Pahl M, Jara A, Bover J, Rodriguez M, Felsenfeld AJ: The set point of calcium and the reduction of parathyroid hormone in hemodialysis patients. Kidney Int 49:226-231, 1996
13. Markowitz GS, Appel GB, Fine PL, et al: Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol 12:1164-1172, 2001
14. Akerstrom G, Rastad J, Ljunghall S: Cellular physiology and pathophysiology of the parathyroid glands. World J Surg 15:672-680, 1991
15. McCarron DA, Lenfesty B, Narasimhan J, Barry JM, Vetto RM, Bennett WM: Anatomical heterogeneity of parathyroid glands in posttransplant hyperparathyroidism. Am J Nephrol 8:388-391, 1988
16. Felsenfeld AJ, Llach F: Parathyroid gland function in chronic renal failure. Kidney Int 43:771-789, 1993
17. Olaizola I, Aznarez A, Jorgetti V, et al: Are there any differences in the parathyroid response in the different types of renal osteodystrophy? Nephrol Dial Transplant 13:15-18, 1998
18. Dunlay R, Rodriguez M, Felsenfeld AJ, Llach F: Direct inhibitory effect of calcitriol on parathyroid function (sigmoid curve) in dialysis. Kidney Int 36:1093-1098, 1989
19. Ettinger B, Genant H, Cann C: Long-term estrogen replacement therapy prevents bone loss and fractures. N Engl J Med 102:319-324, 1985
20. Erlichman M, Holohan T: Bone densitometry: Patients with end stage renal disease. Health Technol Assess 8:1-27, 1996
21. Rossouw JE, Anderson GL, Prentice RL, et al: Writing Group for the Women's Health Initiative Investigators: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-233, 2002
22. Fleisch H: Bisphosphonates: Mechanisms of action. Endocr Rev 19:80-100, 1998
23. Hughes DE, Wright KR, Uy HL, et al: Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res 10: 1478-1487, 1995
24. Berenson JR, Rowen L, Vescio R, et al: Pharmacokinetics of pamidronate disodium in patients with cancer with normal or impaired renal function. J Clin Pharmacol 37:285-290, 1997
25. Machado CE, Flombaum CD: Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 45:175-179, 1996